Fig. 2

Re-diagnose of primary peritoneal cancer and progression on olaparib. A. Progression of rectal lesion after treatment of cetuximab, oxaliplatin and capecitabine for colorectal cancer, rectal lesion indicated by red arrow; B. Hematoxylin-eosin (H&E) staining pictures with the surgical sample. Original magnification× 200; C. Immunohistochemical staining results of Villin (−), CK7 (+++), CK20 (−), ER (++), PAX8 (+++), SATB2 (−) and CDX-2 (−) (original magnification× 100). Antibodies used were listed in Table 1; D. Left: CT scan showing enlarged abdominal lymph nodes (indicated by red arrow); Right: CT scan showing a partial response (PR) after 14 months of olaparib treatment; E. CT scan showing newly onset space occupying lesion (indicated by red arrow) in the right ovary. F. Immunohistochemical staining results of Her2(Br)-, ERCC1 (+), ER (+), PR (−), P53 (+), Ki67 (30%+), P16 (+), WT1 (+), CD31 (+), D2-40 (scattered+) (original magnification× 100). Antibodies used were listed in Table 1